The Prognostic Role of Claudins in Head and Neck Squamous Cell Carcinomas Györgyi A. Nelhűbel Boróka Károly Balázs Szabó Gábor Lotz András Kiss József Tóvári István Kenessey Email author Research First Online: 12 July 2013 Received: 12 April 2013 Accepted: 18 June 2013 DOI :
10.1007/s12253-013-9665-6
Cite this article as: Nelhűbel, G.A., Károly, B., Szabó, B. et al. Pathol. Oncol. Res. (2014) 20: 99. doi:10.1007/s12253-013-9665-6
3
Citations
190
Downloads
Abstract The expression of tight junction proteins is frequently altered in epithelial cancers. The loss of cell-cell adhesion associates with enhanced metastatic potential, which underlies the role of altered expression pattern of tight junction component claudins (CLDNs). Our study assessed the expression of CLDN 1, 2, 3, 4, 7, 8 and 10 in squamous cell carcinoma of the head and neck region (HNSCC) including oropahrynx, larynx, and hypopharynx in comparison to normal epithelial tissue of the same patient. The surgical samples were examined by tissue microarray and immunohistochemistry, the expression was calculated by H-score, which took account of intensity and percentage of positivity as well. Both normal and cancerous tissue proved negative for CLDN 3, 8 and 10. Normal epithelia showed mild expression of CLDN 4, but the minimal positivity disappeared in squamous cancer. In case of CLDN 1 and CLDN 7 we demonstrated significantly increased intensity in cancer, while CLDN 2 showed decreased expression compared with normal epithelium. The normal polarity and distribution of claudins were lost in HNSCC. Moreover, preserved expression of CLDN 2 (but not that of 1 and 7) was associated with better survival, which suggested a potential prognostic role of CLDN 2.
Keywords Claudin Head and neck squamous cell carcinoma Prognosis Immunohistochemistry Tight junction Györgyi A. Nelhübel and Boróka Károly are contributed equally to this work
References 1.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
PubMed CrossRef Google Scholar 2.
Sant M, Aareleid T, Berrino F et al (2003) EUROCARE-3: Survival of cancer patients diagnosed 1990–94–results and commentary. Ann Oncol 14(Suppl 5):v61–118
PubMed CrossRef Google Scholar 3.
Dobrossy L (2005) Epidemiology of head and neck cancer: Magnitude of the problem. Cancer Metastasis Rev 24:9–17
PubMed CrossRef Google Scholar 4.
Guntinas-Lichius O, Wendt T, Buentzel J et al (2010) Head and neck cancer in Germany: A site-specific analysis of survival of the thuringian cancer registration database. J Cancer Res Clin Oncol 136:55–63
PubMed CrossRef Google Scholar 5.
Zimmermann M, Zouhair A, Azria D et al (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiat Oncol 1:11
PubMedCentral PubMed CrossRef Google Scholar 6.
Goerner M, Seiwert TY, Sudhoff H (2010) Molecular targeted therapies in head and neck cancer–an update of recent developments. Head Neck Oncol 2:8
PubMedCentral PubMed CrossRef Google Scholar 7.
Pereira CS, Oliveira MV, Fraga CA et al (2012) Impact of the epithelial dysplasia grading and Ki67 proliferation index in the adjacent non-malignant mucosa on recurrence and survival in head and neck squamous cell carcinoma. Pathol Res Pract 208:651–656
PubMed CrossRef Google Scholar 8.
Cardesa A, Nadal A (2011) Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Panonica Adriat 20:161–173
PubMed Google Scholar 9.
Smilek P, Dusek L, Vesely K et al (2005) Prognostic significance of mitotic and apoptotic index and the DNA cytometry in head and neck cancer. Neoplasma 52:199–207
PubMed Google Scholar 10.
Sadick M, Schoenberg SO, Hoermann K et al (2012) Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 11:Doc08
PubMedCentral PubMed Google Scholar 11.
Morin PJ (2005) Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res 65:9603–9606
PubMed CrossRef Google Scholar 12.
Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2:285–293
PubMed CrossRef Google Scholar 13.
Prat A, Parker JS, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68
PubMedCentral PubMed CrossRef Google Scholar 14.
Szasz AM, Nemeth Z, Gyorffy B et al (2011) Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci 102:2248–2254
PubMed CrossRef Google Scholar 15.
Rangel LB, Agarwal R, D'Souza T et al (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567–2575
PubMed Google Scholar 16.
Michl P, Barth C, Buchholz M et al (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 63:6265–6271
PubMed Google Scholar 17.
Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: Support for use as a therapeutic target. Am J Clin Pathol 121:226–230
PubMed CrossRef Google Scholar 18.
Long H, Crean CD, Lee WH et al (2001) Expression of clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61:7878–7881
PubMed Google Scholar 19.
Borka K, Kaliszky P, Szabo E et al (2007) Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch 450:549–557
PubMed CrossRef Google Scholar 20.
Landers KA, Samaratunga H, Teng L et al (2008) Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer 99:491–501
PubMedCentral PubMed CrossRef Google Scholar 21.
Szasz AM, Nyirady P, Majoros A et al (2010) beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU Int 105:716–722
PubMed CrossRef Google Scholar 22.
Torzsok P, Riesz P, Kenessey I et al (2011) Claudins and ki-67: Potential markers to differentiate low- and high-grade transitional cell carcinomas of the urinary bladder. J Histochem Cytochem 59:1022–1030
PubMed CrossRef Google Scholar 23.
Sobel G, Paska C, Szabo I et al (2005) Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169
PubMed CrossRef Google Scholar 24.
Suzuki M, Kato-Nakano M, Kawamoto S et al (2009) Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci 100:1623–1630
PubMed CrossRef Google Scholar 25.
Neesse A, Griesmann H, Gress TM et al (2012) Claudin-4 as therapeutic target in cancer. Arch Biochem Biophys 524:64–70
PubMed CrossRef Google Scholar 26.
Gyorffy H, Holczbauer A, Nagy P et al (2005) Claudin expression in Barrett's esophagus and adenocarcinoma. Virchows Arch 447:961–968
PubMed CrossRef Google Scholar 27.
Al Moustafa AE, Alaoui-Jamali MA, Batist G et al (2002) Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21:2634–2640
PubMed CrossRef Google Scholar 28.
Ouban A, Hamdan H, Hakam A et al (2012) Claudin-1 expression in squamous cell carcinomas of different organs: Comparative study of cancerous tissues and normal controls. Int J Surg Pathol 20:132–138
PubMed Google Scholar 29.
Szabo B, Nelhubel GA, Karpati A et al (2011) Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47:487–496
PubMed CrossRef Google Scholar 30.
Szekely E, Torzsok P, Riesz P et al (2011) Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder. J Histochem Cytochem 59:932–941
PubMed CrossRef Google Scholar 31.
McCarty KS Jr, Szabo E, Flowers JL et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s–4248s
PubMed Google Scholar 32.
Miyamoto K, Kusumi T, Sato F et al (2008) Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed Res 29:71–76
PubMed CrossRef Google Scholar 33.
Morita K, Tsukita S, Miyachi Y (2004) Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br J Dermatol 151:328–334
PubMed CrossRef Google Scholar 34.
Tokes AM, Kulka J, Paku S et al (2005) Claudin-1, -3 and −4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–305
PubMedCentral PubMed CrossRef Google Scholar 35.
Kramer F, White K, Kubbies M et al (2000) Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum Genet 107:249–256
PubMed CrossRef Google Scholar 36.
Resnick MB, Konkin T, Routhier J et al (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518
PubMed CrossRef Google Scholar 37.
Yoshizawa K, Nozaki S, Kato A et al (2013) Loss of claudin-7 is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. Oncol Rep 29:445–450
PubMed Google Scholar 38.
Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: Expression in normal and neoplastic tissues. BMC Cancer 6:186
PubMedCentral PubMed CrossRef Google Scholar © Arányi Lajos Foundation 2013
Authors and Affiliations Györgyi A. Nelhűbel Boróka Károly Balázs Szabó Gábor Lotz András Kiss József Tóvári István Kenessey Email author 1. Department of Experimental Pharmacology National Institute of Oncology Budapest Hungary 2. Department of Otolaryngology and Head and Neck Surgery Semmelweis University Budapest Hungary 3. 2nd Department of Pathology Semmelweis University Budapest Hungary